Study results from ASH 2019 shed light on treatment
Two-year follow-up confirms initial findings of the INO-VATE trial
Lower toxicity than conventional chemo
Study’s findings are welcome news
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Drug targets CD33 to produce high remission rates
Phase 3 results reported in NEJM
Promising clinical trials underway
Superior outcome for young adults on pediatric regimen
SGN-CD33A demonstrates encouraging antileukemic activity